Drug pipelines, trial readouts, payers and medtech.
24 report(s) in the archive
The French drugmaker and its US partner widened a deal that could be worth up to $8 billion as both companies push deeper into shared drug development.
Sanofi and Regeneron expanded their partnership in a deal that includes a $1 billion upfront payment and a total value of up to $8 billion.
A federal court ruled against Liquidia on two patent claims, handing a win to rival United Therapeutics and threatening the drugmaker's product pipeline.
Liquidia shares fell sharply on September 30 after a court sided with United Therapeutics on two patent infringement claims.
The French biotech's shares gained after it said royalties on its liver drug Iqirvo have tripled, extending its cash runway well beyond 2028.
Genfit shares rose 4% after the company reported tripled royalties from Iqirvo and said its cash runway now extends beyond 2028.
Warsh's comments point to a tougher rate environment, but analysts say pharmaceutical dividend payers may hold up better than feared.
Kevin Warsh signaled the Federal Reserve is likely to keep interest rates higher for longer, a stance that could pressure pharmaceutical stocks but by less than some investors expect.
The bank started coverage of the pulmonary-disease drugmaker with a Sell while giving fellow gene-therapy name MeiraGTx a Neutral.
Goldman Sachs opened coverage on United Therapeutics with a Sell rating, a rare bearish call on a biotech that has built a lucrative franchise in pulmonary arterial hypertension drugs.
A failed trial targeting Lp(a), a blood fat linked to heart attacks, dragged down rival drugmakers betting on the same approach.
Novartis's failed trial for a cholesterol-lowering drug that targets Lp(a) sparked a broad selloff across biopharma stocks betting on the same cardiovascular strategy.
A cluster of insider sales spanning Illumina, Krystal Biotech, CrowdStrike, Warner Bros. Discovery and NMI Holdings raises the question of whether executives see limited upside from here.
Illumina director Keith Meister sold $57.2 million in stock, the largest of at least seven insider sales disclosed in the period, together totaling well over $80 million across unrelated sectors.
Evercore ISI cut its rating on Ultragenyx after a failed trial while Rothschild Redburn downgraded Moderna over how the stock is priced.
Two separate analyst downgrades hit biotech stocks, with Ultragenyx cut on a clinical trial failure and Moderna cut on valuation grounds.
The biotech turned to debt markets for fresh capital, a move investors read as dilutive and defensive.
Moderna's stock dropped after the company announced a $2 billion convertible notes offering, a financing move that raises the prospect of future share dilution.
CEO, CIO, legal chief and pharma chief all filed insider sales this month, though most retained the bulk of their holdings.
Cardinal Health's CEO divested 125,000 shares across two trading sessions, part of a cluster of insider sales from four top executives that followed the stock's 57%-58% one-year gain.
A cluster of multimillion-dollar stock sales by insiders at Meta, Apple, Tapestry, Coeur Mining and others coincided with a $156.9 million exit by Chime Financial's largest shareholder.
DST Global Advisors, a 10% owner of Chime Financial, sold $156.9 million in stock, the largest of more than a dozen insider sales disclosed across sectors including tech, retail, mining and biotech.
Stantec's record $9.2 billion backlog, EquipmentShare's 26% revenue growth and BBB Foods' 39% top-line expansion contrast sharply with Comscore's 11.3% revenue decline and Wolfspeed's restructuring, exposing a widening quality divide.
A heavy transcript session revealed a sharply two-tiered market: capital-project and value-retail names delivered record results, while advertising measurement, legacy semiconductors and small-cap software struggled with structural demand erosion.
A clinical breakthrough in Moderna's oncology vaccine program lifted the wider biopharmaceutical complex, extending a nascent recovery in a sector that has endured a multi-year derating on pricing pressure and patent-cliff anxiety.
Moderna's cancer-vaccine breakthrough triggered a sector-wide rally in biopharma stocks, accelerating an upswing that had already begun to reverse years of underperformance. The data point revives the platform thesis for mRNA beyond infectious disease and pulls capital back toward clinical-stage names including smaller RNA-therapeutics developers.
Mowi's record harvest and 23% profit growth contrast with Multiconsult's margin-led beat on flat organic revenue and sharp single-stock punishments across MedTech and industrials.
Q2 2026 European results reveal a widening dispersion between volume-driven earnings growth and companies relying on cost discipline, with the market rewarding structural demand and penalizing stalled top-lines.
The FTSE-listed pharmaceutical group discontinued a late-stage lung cancer study of its bispecific candidate after a data setback, even as Enhertu delivered a progression-free survival benefit in a separate lung indication — leaving the stock higher on the day.
AstraZeneca discontinued a Phase 3 trial of volrustomig in lung cancer following disappointing data, a meaningful blow to its next-generation immuno-oncology ambitions. The negative headline was cushioned by positive progression-free survival results for Enhertu in a lung cancer setting, and shares traded higher as investors weighted the commercial-stage readout more heavily than the pipeline write-down.
Snowflake, Rhythm Pharmaceuticals and Krystal Biotech executives lead more than $40 million in disclosed disposals, with Dutch Bros the rare insider buy
A dense cluster of Form 4 filings shows heavy insider distribution across software and biotechnology, led by a $16.8 million Snowflake director sale and roughly $15.5 million of combined Rhythm Pharmaceuticals executive sales, while insider buying was limited to a single Dutch Bros board purchase.
A concentrated round of reiterations tied to regulatory milestones, patent litigation and quarterly execution underscores that small-cap biotech is being underwritten on catalysts rather than sector beta.
H.C. Wainwright reiterated constructive ratings on four clinical and commercial-stage biotechs on the same session, citing regulatory progress at Pharvaris, a $36 target on 4D Molecular, patent-suit developments at Cytokinetics and a strong quarter at CorMedix.
AIG executive chair Peter Zaffino disposed of more than $18 million in stock, joined by sales at Amgen, Guardant Health, Septerna, Knight-Swift and Red Cat — a breadth of distribution that warrants monitoring even where plans are pre-scheduled.
A concentrated day of Form 4 activity showed AIG's Zaffino selling over $18m, Guardant Health's CPO $7.6m, Amgen SVP $1.35m, Septerna's president/COO $1.1m, Red Cat director $310,600 and Knight-Swift director $115k, with only a token $4,612 buy at DLH Holdings on the other side.
A dense batch of Q2 2026 transcripts shows diagnostics, infusion and payments franchises compounding double-digit growth while pet food, RV batteries and legacy services guide lower — a widening quality dispersion inside the same tape.
Natera oncology volumes rose 57.2%, iRhythm revenue climbed 20% with raised guidance, ICU Medical posted record Infusion Systems revenue on 12% organic growth, and Nu Holdings cleared $1B in quarterly profit. Offsetting that, Post's pet food volumes fell 7.8%, i3 Verticals cut guidance, and Dragonfly Energy is pivoting away from a soft RV end market.
Morgan Stanley initiates Achieve Life Sciences at overweight and PTC Therapeutics moves on a Fabry gene therapy acquisition, while EVgo and Highwoods Properties absorb rating downgrades
A heavy day of sell-side repositioning tilted toward biotech and specialty healthcare, with new overweight coverage and M&A-driven pipeline expansion, even as EV charging and office REIT exposures were marked down on execution and valuation grounds.